
The latest Fujifilm financial results are out (Q1/2025 – April to June 2025).
Interestingly, Fujifilm makes an estimate of the impact of U.S. tariffs for each segment, except for the imaging division
- health care = – 4.0 billion yen
- electronics = – 1.0 billion yen
- business innovation = – 1.0 billion yen
- imaging = no information
A positive mention (strong sales) goes to the Fujifilm X100VI, Fujifilm X-T50, Fujifilm GFX100SII and Fujifilm X-M5 and as far as Fujifilm GFX100RF and X half goes, they just say they “contributed” to the results. In the Instax world sales were strong for instax WIDE 400 and instax WIDE Evo.
Also interesting: professional imaging (mainly X and GFX) is growing much stronger than consumer imaging (mainly Instax).
In the latest report, consumer imaging sales (mainly Instax) reached ¥77.3 billion, while professional imaging sales (mainly X and GFX) brought in ¥68 billion.
It’s quite astonishing that X/GFX sales are now making Fujifilm almost as much money as Instax sales, which the Fujifilm CEO called their new goldmine. I guess that’s a promising trend for our beloved X/GFX series.
In short:
- Strong demand for instant photo systems and digital cameras drove revenue by 11.2% year-over-year to JPY145.3 billion and operating income surged by 28.4% year-over-year to JPY41.8 billion.
- In the Consumer Imaging business, consistent demand for instax™ instant photo systems contributed to higher revenue.
- In the Professional Imaging business, revenue growth was supported by the strong performance of the X Series and GFX Series cameras.
Fujifilm’s imaging forecast remains the same as the one issued in May 2025, with no updates in the latest report.
Fujifilm Announces Financial Results for the First Quarter Ended June 30, 2025